Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Sermorelin vs CJC-1295 + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Sermorelin has stronger documented evidence (Discontinued (FDA approval 1990; US withdrawal 2008)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Sermorelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Sermorelin

Discontinued (FDA approval 1990; US withdrawal 2008)

CJC-1295 + Ipamorelin

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: injection site reactions. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Sermorelin CJC-1295 + Ipamorelin
Class GHRH analog GHRH analog + selective GHRP blend (GH-secretagogue stack)
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm).
Route SC injection SC injection
Half-life ~10-20 min CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs
Dosage (research) 200-500 mcg SC at bedtime daily 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off
Evidence tier Discontinued (FDA approval 1990; US withdrawal 2008) Anecdotal + Animal Studies
Research depth 149 indexed (PubMed 122 · CT 17 · EPMC 10) 5 indexed (PubMed 0 · CT 0 · EPMC 5)
Availability Compounding Restricted Compounding Restricted
Reported risks Injection site reactions; headache; flushing Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Sermorelin or CJC-1295 + Ipamorelin?

Sermorelin has stronger documented evidence (Discontinued (FDA approval 1990; US withdrawal 2008)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Sermorelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Sermorelin and CJC-1295 + Ipamorelin?

Sermorelin is classed as GHRH analog; CJC-1295 + Ipamorelin is classed as GHRH analog + selective GHRP blend (GH-secretagogue stack). Reported mechanism: Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release; CJC-1295 + Ipamorelin, Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). Reported half-life: Sermorelin, ~10-20 min; CJC-1295 + Ipamorelin, CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs. Routes in published studies: Sermorelin, SC injection; CJC-1295 + Ipamorelin, SC injection.

Which has stronger evidence, Sermorelin or CJC-1295 + Ipamorelin?

Sermorelin and CJC-1295 + Ipamorelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 149 indexed studies. CJC-1295 + Ipamorelin is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 5 indexed studies.

Which is more accessible, Sermorelin or CJC-1295 + Ipamorelin?

Neither Sermorelin nor CJC-1295 + Ipamorelin is an FDA-approved drug. Catalog status: Sermorelin, Compounding Restricted; CJC-1295 + Ipamorelin, Compounding Restricted.

Are Sermorelin and CJC-1295 + Ipamorelin ever combined?

Sermorelin and CJC-1295 + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…